Tacit Therapeutics created RNA-targeting treatments for devastating diseases.
Tacit Therapeutics has raised $19.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Tacit Therapeutics's investors include National Science Foundation, Civilization Ventures, KdT Ventures, Michigan Capital Network, Eisai Innovation.
Tacit Therapeutics is headquartered in South San Francisco, United States.
Tacit Therapeutics created RNA-targeting treatments for devastating diseases.
Tacit Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tacit Therapeutics — Funding & Investors." VCBacked, March 9, 2026, https://www.vcbacked.co/company/tacit-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Tacit Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/tacit-therapeutics
{{cite web |title=Tacit Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tacit-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated